[A25-121] Ixekizumab (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2026
Project no.:
A25-121
Commission:
Commission awarded on 25.09.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-121
| Project no. | Title | Status |
|---|---|---|
| A25-120 | Ixekizumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-66 | Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-65 | Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-14 | Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-07 | Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |